Sartorius AG
Company Profile
Business description
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
Contact
Otto-Brenner-Strasse 20
GottingenNI37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
13,685
Stocks News & Analysis
stocks
Short-term pain for long-term gain for undervalued ASX share
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,010.10 | 117.10 | -1.28% |
CAC 40 | 7,688.60 | 34.35 | 0.45% |
DAX 40 | 23,569.17 | 81.84 | 0.35% |
Dow JONES (US) | 45,295.81 | 249.07 | -0.55% |
FTSE 100 | 9,136.80 | 20.11 | 0.22% |
HKSE | 25,337.36 | 159.19 | -0.62% |
NASDAQ | 21,279.63 | 175.92 | -0.82% |
Nikkei 225 | 41,938.89 | 371.60 | -0.88% |
NZX 50 Index | 13,074.81 | 58.35 | -0.44% |
S&P 500 | 6,415.54 | 44.72 | -0.69% |
S&P/ASX 200 | 8,738.80 | 120.20 | -1.36% |
SSE Composite Index | 3,813.56 | 44.58 | -1.16% |